Physician interpretation of genomic test results and treatment selection
CONCLUSIONSPhysicians are aware of recurrent mutations in actionable genes on “hotspot” panels. As larger genomic panels are used, there may be a growing need for annotation of actionability. Decision support to increase awareness of genomically relevant trials and novel treatment options for recurrent mutations (eg, KRAS) also are needed. Cancer 2017. © 2017 American Cancer Society.
Source: Cancer - Category: Cancer & Oncology Authors: Lauren L. Brusco, Chetna Wathoo, Kenna R. Mills Shaw, Vijaykumar R. Holla, Ann M. Bailey, Amber M. Johnson, Yekaterina B. Khotskaya, Beate C. Litzenburger, Nora S. Sanchez, Jia Zeng, Elmer V. Bernstam, Cathy Eng, Bryan K. Kee, Rodabe N. Amaria, Mark J. Ro Tags: Original Article Source Type: research